Quarterly report pursuant to Section 13 or 15(d)

Condensed Statements of Stockholders Equity (Deficit) (Unaudited)

v3.22.0.1
Condensed Statements of Stockholders Equity (Deficit) (Unaudited) - USD ($)
Series A Preferred Stock [Member]
Common Stock [Member]
Additional Paid-in Capital [Member]
Note Recievable for Common Stock Related Party [Member]
Retained Earnings [Member]
Total
Beginning balance, value at Apr. 30, 2020 $ 75 $ 6,476 $ 27,584,227 $ (14,983,200) $ (11,785,869) $ 821,709
Shares outstanding biginning balance at Apr. 30, 2020 750,000 64,762,858        
Stock-based compensation to employees and consultants 1,479,231 1,479,231
Shares outstanding ending balance 750,000          
Net loss (3,789,734) (3,789,734)
Proceeds from note receivable – related party for common stock 99,905 99,905
Fair value of warrants issued in connection with convertible notes 78,642 78,642
Fair value of warrants issued in connection with convertible notes- related party 14,300 14,300
Ending balance, value at Jan. 31, 2021 $ 75 $ 6,476 29,156,400 (14,883,295) (15,575,603) (1,295,947)
Shares outstanding ending balance at Jan. 31, 2021 750,000 64,762,858        
Beginning balance, value at Oct. 31, 2020 $ 75 $ 6,476 28,666,695 (14,883,295) (14,456,719) (666,768)
Shares outstanding biginning balance at Oct. 31, 2020 750,000 64,762,858        
Stock-based compensation to employees and consultants 489,705 489,705
Net loss (1,118,884) (1,118,884)
Ending balance, value at Jan. 31, 2021 $ 75 $ 6,476 29,156,400 (14,883,295) (15,575,603) (1,295,947)
Shares outstanding ending balance at Jan. 31, 2021 750,000 64,762,858        
Beginning balance, value at Apr. 30, 2021 $ 75 $ 6,743 33,721,859 (14,883,295) (16,832,437) $ 2,012,945
Shares outstanding biginning balance at Apr. 30, 2021 750,000 67,429,525       67,429,525
Stock-based compensation to employees and consultants 3,150,801 $ 3,150,801
Proceeds from stock option exercise $ 300 900 1,200
Share-based Compensation Arrangement by Share-based Payment Award, Options, Exercises in Period   3,000,000        
Conversion of Series A convertible stock $ (75) $ 1,500 (1,425)
Shares outstanding ending balance (750,000) 15,000,000        
Net loss (8,492,661) (8,492,661)
Issuance of common stock for restricted stock awards 21 (21)
Stock Issued During Period, Shares, New Issues           212,500
Proceeds from sale of common stock and warrants-related party, net $ 133 1,999,867 $ 2,000,000
Stock Issued During Period Shares New Issues2   1,333,333        
Proceeds from initial public offering, net of underwriters' discounts and commissions and issuance costs of $1.5 million $ 288 12,911,168 12,911,456
Stock Issued During Period Shares New Issues3   2,875,000        
Issuance of shares of common stock for conversion of note   $ 25 378,373 378,398
Issuance of Shares of Common Stock for Conversion of Debt Shares   252,265        
Ending balance, value at Jan. 31, 2022 $ 9,010 52,161,522 (14,883,295) (25,325,098) 11,962,139
Shares outstanding ending balance at Jan. 31, 2022   90,102,623        
Beginning balance, value at Oct. 31, 2021 $ 8,885 50,652,054 (14,883,295) (22,752,233) 13,025,411
Shares outstanding biginning balance at Oct. 31, 2021   88,850,358        
Stock-based compensation to employees and consultants 1,130,795 1,130,795
Proceeds from stock option exercise $ 100 300 400
Share-based Compensation Arrangement by Share-based Payment Award, Options, Exercises in Period   1,000,000        
Conversion of Series A convertible stock $ 25 378,373 378,398
Shares outstanding ending balance   252,265        
Net loss (2,572,865) (2,572,865)
Ending balance, value at Jan. 31, 2022 $ 9,010 $ 52,161,522 $ (14,883,295) $ (25,325,098) $ 11,962,139
Shares outstanding ending balance at Jan. 31, 2022   90,102,623